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Abstract
Background: Non-motor symptoms are present in Parkinson’s disease (PD) and a key determinant of quality of life. The
Non-motor Symptoms Scale (NMSS) is a validated scale that allows quantifying frequency and severity (burden) of NMS. We
report a proposal for using NMSS scores to determine levels of NMS burden (NMSB) and to complete PD patient
classification.
Methods: This was an observational, cross-sectional international study of 935 consecutive patients. Using a distribution of
NMSS scores by quartiles, a classification based on levels from 0 (no NMSB at all) to 4 (very severe NMSB) was obtained and
its relation with Hoehn and Yahr (HY) staging, motor and health-related quality of life scales was analyzed. Concordance
between NMSB levels and grouping based on clinician’s global impression of severity, using categorical regression, was
determined. Disability and HRQoL predictors were identified by multiple regression models.
Results: The distribution of motor and QoL scales scores by HY and NMSB levels was significantly discriminative. The
difference in the classification of cases for both methods, HY and NMSB, was significant (gamma=0.45; ASE=0.032).
Concordance between NMSB and global severity-based levels from categorical regression was 91.8%, (kappaw=0.97). NMS
score was predictor of disability and QoL.
Conclusions: Current clinical practice does not address a need for inclusion of non-motor scores in routine assessment of
PD in spite of the overwhelming influence of NMS on disability and quality of life. Our data overcome the problems of ‘‘pure
motor assessment’’ and we propose a combined approach with addition of NMSB levels to standard motor assessments.
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Introduction
Parkinson’s disease (PD) is a progressive, complex disorder
characterised by motor symptoms, such as bradykinesia, rest
tremor, and rigidity but also a wide range of non-motor symptoms
(NMS) that contribute to significant morbidity and disability.
NMS such as sleep dysfunction, dementia and depression are key
determinants of patients’ health-related quality of life (HRQoL)
[1,2]. Furthermore, while motor heterogeneity of PD is well
established, clinical subtyping of Parkinson’s based on non-motor
symptoms has not been clearly established [3–6]. A pathological
basis of non-motor endophenotypes has been suggested while
subtyping of PD using latent class analysis indicate clusters with
varying and sometimes dominant non-motor load [4,5,7].
Furthermore, a distinct phase (phase 2) associated with specific
non-motor symptoms has been proposed in the natural history of
PD [6,8].)
Currently, PD severity is often rated using Hoehn and Yahr
staging (HY) which purely reflects the motor severity of disease
and compromise of balance/gait. The diagnosis of PD is made
using the UK Parkinson’s Disease Society Brain Bank clinical
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mainly related to substantia nigra pathology [9,10]. Interestingly,
NMS such as sleep, autonomic and executive dysfunction, pain,
and fatigue, may occur early or at a pre-motor phase and increase
in prevalence and severity over time [11–15]. Importantly, it is not
one NMS but a combination of several NMS that may serve in
future to underpin refining diagnosis and management of PD [15].
In the clinic, current practice does not include obligatory
assessment of non-motor scores using validated scales in spite of
the overwhelming effect of NMS on quality of life. As a result,
many NMS may remain undetected and lead to suboptimal care
as reported from a recent European survey [16]. In this article, we
provide the framework for improving our clinical assessment of PD
in the clinic by incorporating a ‘‘snapshot’’ burden of NMS score
to the existing motor assessments. Specific levels of burden of
NMS (NMSB) are described based on an analysis of detailed NMS
data available from an international database of consecutive PD
cases. This pragmatic and score-based assessment paradigm can
be easily adopted in the clinic taking into account both the severity
of the motor and non-motor burden to improve the current system
of classification.
Methods
Design
This was an observational, multi centre, cross-sectional,
international study.
Patients
Data from 951 consecutive PD patients diagnosed by a
neurologist/geriatrician (movement disorders specialists) accord-
ing to international recognized diagnostic criteria [10,14] were
included in the multipurpose database built and secured in the
Alzheimer Centre Reina Sofia Foundation, Carlos III Institute of
Health, Madrid.
Exclusion criteria were: Atypical and secondary parkinsonism
(multiple system atrophy, progressive supranuclear palsy, etc);
concomitant severe systemic disease (e.g., clinically severe organ
failure such as cardiac failure, hepatic failure) or condition
interfering with assessments required for study (e.g., blindness);
inability to read, understand, or answer written questionnaires, or
inability to provide informed consent. Overt dementia impeding
evaluation, as per the clinical judgment, was a specific exclusion
criterion.
Data. The data were collected from two independent series
collected by the main authors (KRC and PMM) using a common
protocol for clinical assessments and data capture. The bulk of the
data used for the present study arose from a cross-sectional study
designed to validate the NMS scale and data at baseline from a
long-term international longitudinal study addressing the natural
history of PD non-motor symptoms and has been published
previously [2,17].
Setting and locations. Departments of Neurology and
Movement Disorder Units from centres in 15 countries of
America, Asia, and Europe (ref. 17 and Annex S1).
Dates. The final database was built from data collected from
2007–2011.
Ethical aspects
The non-motor scale validation studies received ethical
approval from Carlos III Institute of Health, Madrid, Spain
[2,17] and research ethics committee at University Hospital
Lewisham, London, UK [18]. The longitudinal NMS natural
history study has been approved in all relevant institutions and is
included in UK Department of Health portfolio of approved
studies. All participant researchers obtained approval from their
respective local EC/IRB and patients signed their informed
consent before inclusion.
Assessments
In addition to socio-demographic and historical data, the
following instruments were applied:
The Scales for Outcomes in Parkinson’s Disease-Motor
(SCOPA-Motor), has 3 sections: A. Examination (10 items); B.
Activities of daily living (ADL, 7 items); and C. Complications (4
items). Possible responses per item range from 0 (normal) to 3
(severe) with total score between 0 and 75 [19,20].
The Non-Motor Symptoms Scale (NMSS) has 30 items, nine
domains: cardiovascular (2 items), sleep/fatigue (4 items), mood/
cognition (6 items), perceptual problems/hallucinations (3 items),
attention/memory (3 items), gastrointestinal tract (3 items), urinary
function (3 items), sexual function (2 items), and miscellaneous (4
items). Each item scores on a multiple of severity (from 0 to 3) and
frequency scores (from 1 to 4) and the theoretical range of the
NMSS total score is 0 to 360 [17,18]. We refer to this score as
‘‘burden’’ (NMSB) since values integrate frequency and severity.
The original Hoehn and Yahr (HY) classification was used in
this study [9].
The Clinical Impression of Severity Index (CISI-PD) addresses:
motor signs; disability; motor complications; and cognitive status.
Items are rated on a 7-point scale (from 0, normal, to 6, very
severe) and total score, ranges from 0 to 24 [21,22].
The EQ-5D is a generic, preference-based HRQoL measure
[23,24]. It includes a descriptive part of 5 items (profile), that can
then be converted into an EQ-Index (from 1, perfect health state,
to 0, death), and a visual analogue scale (EQ-VAS) for assessment
of current health state (from 0, the worse imaginable health state,
to 100, best imaginable health state).
The PDQ-8 is a specific instrument for assessment of HRQoL
in PD [25]. It includes 8 items, each one scoring from 0 to 4. The
PDQ-8 Summary Index is expressed as percentage of the sum of
the items scores on the maximum possible scale score. Both, EQ-
5D and PDQ-8 are instruments recommended for use in PD by an
ad hoc Movement Disorder Society task force [26].
For all the aforementioned scales, with the exception of the EQ-
5D index and VAS, the higher the score, the worse the assessed
construct. The NMSS captures symptoms over the last month and,
in patients with fluctuations, the motor and non-motor evaluations
were carried out in an ‘‘on’’ state.
Data analysis
Descriptive statistics were used to determine the characteristics
of the sample in relation to socio-demographic aspects, historical
data, and evaluations.
Using the cut-off points of the interquartile range (centiles 25,
50, and 75), the following NMSS score limits and NMSB levels
were established: 0 (no NMS); 1–20 (Mild); 21–40 (Moderate); 41–
70 (Severe); and $71 (Very severe). Once categories of the NMSS
total score were established, the ability of that grouping to
discriminate among patients according to the other variables in the
study was determined (Kruskal-Wallis test). The difference in
proportions between NMSB levels and HY stages was tested using
the Goodman and Kruskal’s gamma. Agreement between
classifications was explored using weighted kappa with quadratic
weights. Correlation between scale scores were determined by
Spearman rank correlation coefficients and the difference between
correlation coefficients was tested through the two tailed Fisher’s z
transformation. Multiple regression models were built to identify
Grading the Parkinson’s Disease Non-Motor Burden
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5D, PDQ-8) predictors.
A post-hoc analysis was carried out using the CISI-PD as a
criterion for global PD severity [21]. CISI-PD total scores have
been previously categorized in global levels of PD severity (1–7
points=mild; 8–14: moderate; and $15 points=severe) [22] and
this classification was used to create NMSS score categories to be
compared with those obtained by means of centiles. Due to skewed
distribution of the NMSS scores and the CISI-PD ordinal level of
measure a categorical regression analysis was used to determine
the association between NMSS scores and CISI-PD severity levels.
Data analysis was carried out using Stata 11.2 (StataCorp,
College Station, Texas).
Results
Nine hundred and fifty one patients, 62.6% males, were
included in the study. The clinical characteristics of the sample are
displayed in the Table 1. The distribution of patients by HY
ratings was (n=949): stage 1, 125 (13.2%); stage 2, 412 (43.4%);
stage 3, 284 (29.9%); stage 4, 108 (11.4%); and stage 5, 20 (2.1%).
Of the 835 patients with available data on treatment, 81.0%
received treatment with levodopa; 58.3%, dopamine agonists;
8.0%, selegiline; 15.0%, rasagiline; 15.6%, amantadine; and 1.1%,
apomorphine. Levodopa and dopamine agonists were combined
in 47.3%; 44 patients (5.3%) were untreated; and 35 (3.7%) had
undergone deep brain stimulation surgery for PD.
There were 19 missing scores in NMSS domains from sixteen
patients (1.7%). Due to the structure of the scale, imputation was
not carried out and NMSS total score refers to the 935 patients
(98.3%) with full data. The number of NMS and the NMSS scores
related to each NMSB level are shown in Table 2.
Table 3 shows scores from other disease-related variables in the
study broken down by NMSB levels. As a whole, figures indicate a
significant worse state in all aspects as the NMSB level increases.
The same performance was obtained with grouping by HY stages,
but figures were clearly different between both methods (Table 3).
The correlation coefficient between motor disturbance ratings
(SCOPA-Motor) and the non-motor symptoms (Non-Motor
Symptoms Scale) was 0.43 (p,0.0001) in the series, ranging from
0.18 to 0.36 (weak correlation; p=0.01–0.0001) for patients in HY
stages 1 to 4 and only showing a high correlation for patients in
stage 5 (rS=0.65; p,0.0001).
The corresponding distribution of patients by HY stages and
NMSB levels is shown in Table 4. The agreement between these
ratings of severity was weak (kappa=0.39; CI95%: 0.37–042) and
the difference in the classification of cases was statistically
significant (gamma=0.45, ASE=0.032).
The following ranges and categories were obtained from the
categorical regression between NMSS score and CISI-PD severity
levels: 0 (absence of NMS); 1 to 15 points (mild NMS burden); 16
to 40 points (moderate NMS burden); 41 to 65 (severe NMS
burden); and $66 points (very severe NMS burden). The
coincidence between classification of patients by these levels from
categorical regression and those based on the interquartile range
was 858/935 (91.8%), with an agreement (kappa)=0.97 (CI95%:
0.96–0.97). Discrepancies (8.2%) were restricted to the NMSB
levels 1 (n=55) and 3 (n=22).
Disability, as per the SCOPA-Motor, Part B. ADL scores, was
closely associated to motor impairment (motor examination +
motor complications (rS=0.76), but correlated moderately with
NMSS scores (rS=0.47) (Fisher’s z=211.83, 2-tailed p,0.0001).
Concerning HRQoL, EQ-5D index correlated with motor
impairment (rS=20.53) and NMSS (rS=20.50) (Fisher’s
z=0.55; p=0.29) and PDQ-8 scores correlated with both motor
impairment and NMSS scores (rS=0.48 and 0.51, respectively;
Fisher’s z=0.86; 2-tailed; p=0.38).
After exclusion of interaction and co-linearity, age, sex, motor
impairment (SCOPA-Motor, Part A. Examination), and NMSS
scores were introduced as independent variables in a multiple
regression model with SCOPA-Motor, Part B. ADL as dependent
variable (F=436.77; adjusted R
2=0.65; p,0.0001) while similar
regression models examined EQ-5D (F=169.17; adjusted
R
2=0.43; p,0.0001) and PDQ-8 (F=150.20; adjusted
R
2=0.39; p,0.0001) as dependent variable. The most powerful
independent predictors were: for ADL, motor impairment
(standardized beta=0.68) followed by NMS (beta=0.20); for
PDQ-8 scores, NMSS scores (beta=0.39) followed by motor
impairment (beta=0.37); and for EQ-5D motor disorder followed
by NMS (motor=0.39; NMS=0.37). In all models, age and sex
had a null or weak influence (beta,0.10).
Discussion
The key outcomes of this study are:
1. A new strategy for clinical classification of PD patients using
the NMSS in 5 stratified levels of burden (0–4=no NMS, 4=
very severe load of NMS, Tables 2 and 3). This simple
assessment could be added to existing motor-based staging (i.e.,
HY) to complement PD assessment and avoid overlooking the
weight of the NMS.
2. Confirmation of the significant influence of NMSB on disability
and quality of life, highlighting the need to include a NMS
evaluation for a complete assessment of PD patients.
This paper is aimed to propose a pragmatic, data driven clinical
assessment system for PD to meet a key unmet need and a clinical
challenge. We are not trying to discriminate PD patients from a
control population neither is the study designed to address
causation of NMS such as the role of drug therapy and
pathogenesis of NMS. Instead, the NMSB classification would
flag up the level of NMS load using a numerical cutoff along with
motor staging to describe better the patient situation. In addition,
the NMSB classification will help the physician to establish
Table 1. Main characteristics of the sample.
Mean SD Median Range
Age at study 64.43 9.90 — 34–89
Age at onset of Parkinson’s disease 56.43 10.78 — 25–89
Duration of the disease 7.99 5.78 — 0–40
SCOPA-Motor Total score 21.15 12.03 19 1–72
SCOPA-Motor A. Examination 11.64 6.61 10 0–41
SCOPA-Motor B. Activities of daily living 6.84 4.19 7 0–21
SCOPA-Motor C. Complications 2.69 3.00 2 0–12
Clinical Impression of Severity Index 8.25 4.61 8 0–24
EQ-5D index (time trade-off) 0.61 0.34 0.68 20.65–1
EQ-5D visual analogue scale 62.43 22.11 65 0–100
PDQ-8 summary index 30.46 19.94 28.12 0–100
Non-Motor Symptoms Scale total score 50.41 41.57 39 0–225
SD: Standard deviation. SCOPA: Scales for Outcomes in Parkinson’s Disease.
PDQ-8: Parkinson’s Disease Questionnaire-8 items.
doi:10.1371/journal.pone.0057221.t001
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manifestations which importance may be overlooked [16,27].
Although NMS burden increases with increasing severity of
other domains affected by PD, the correlation between motor
disorder, as rated by the SCOPA-Motor, and NMS was moderate
(rS=0.43), showing a loose association in all stages except the most
advanced one. Most importantly, a clear discordance between
motor and non-motor disturbance exists, with patients in the
milder stages of motor disorder having considerable non-motor
burden. For example, over one third (34.5%) of patients in HY
stage 1 and 2 had severe or very severe NMSB in the present study
(Table 4). This fact justifies the need, for a more complete
assessment, of a specific method for classification of PD patients
according to NMSB.
The proposed classification was supported by a benchmark
based on clinician’s global impression of severity (CISI-PD).
Categorical regression allowed assignment of NMSS scores to
CISI-PD ordinal categories of severity [22] and this distribution
showed an excellent concordance with the proposed classification
based on quartiles (agreement, 91.8%; kappaw=0.97, ‘‘almost
perfect’’) [28].
The importance of NMS in PD is well established and several
observational and controlled studies have reported the high
prevalence of NMS in PD [1,29–31]. Patients, irrespective of
early or advanced disease, rate NMS as one of their ‘‘first choice’’
symptoms of concern [32] and untreated PD patients show a high
burden of NMS [30,33]. These observations and our data confirm
the fact that when questioned systematically very few patients are
free of any NMS. Our cohort of patients included drug naive and
advanced cases on a range of drug therapies and all HY stages
(Tables 1 and 3). A wide range of patients’ age was spanned in our
study, although the relatively low mean age (64 years) reflects the
fact that the oldest PD patients are typically not referred to the
movement disorders clinics and, therefore, were under-represent-
ed in this cohort. We feel this is a reasonably representative cohort
of PD patients assisted in departments of neurology and
specialized units and shows how NMS occurs in early, moderately
advanced and advanced PD, as also reported by the PRIAMO
study [29].
We also corroborate that the burden of NMS is a key
determinant of quality of life in PD [2,29,34,35] and indeed this
is one of the key outcomes of this work. This is illustrated by the
regression models where the burden of NMS appears to be as
important a predictor of quality of life (EQ-5D and PDQ-8) as is
motor impairment. Interestingly, when both motor and non-motor
impairment are taken into account, age had a negligible influence
on quality of life, a finding that emphasises the considerable
impact of both motor and non-motor disabilities on patients.
These are important issues as the basis of assessment and
therapeutic strategies in PD should be driven by impact on
quality of life [36,37].
What then could be the clinical implications if NMSB
classification as proposed in this paper is adopted in ‘‘real life’’
practice? Firstly the proposed numerical grading should help
improved patient care by alerting the clinician for the need for
addressing treatable NMS [1]. In current clinical practice, NMS
burden is often not assessed and a European study reported that
various NMS were never declared to health care professionals in
60% of cases compromising care [16]. Secondly, the statistical
concordance between HY staging and NMS classification denotes
only weak agreement (when k=0.21 to 0.40) [28] between these
two assessment paradigms. For instance, as shown in Table 4, only
5 patients in HY stages 1 or 2 reported no NMSB whereas 76
experienced NMSB grade 4 (very severe). Conventionally, HY
stage 1 and 2 represent mild PD, but this qualification cannot be
supported attending the load of NMS, any domain/s they belong.
The non-motor manifestations present in PD may be very variable
in number and type and they maintain only a moderate
association with the motor disturbances. Clinical and neuropath-
ological data are now emerging supporting our concept of the
aforementioned non-motor dominant endophenotype and the
clinical heterogeneity of PD [5,33,38].
The strength of this analysis is the large number of patients
included spanning early and untreated to very advanced motor
Table 2. Non-Motor Symptoms Scale domains scores broken down by burden levels.
Non-Motor Symptoms Burden Levels
No Mild Moderate Severe Very severe
0 1 234
NMSS score range 0 1–20 21–40 41–70 $71
Number of NMS 0.0060.00 5.4362.97 9.6563.77 12.3663.67 17.34665.15
1. Cardiovascular 0.0060.00 0.3660.84 0.7961.70 1.4662.31 3.9864.76
2. Sleep/Fatigue 0.0060.00 1.8262.28 5.1864.59 9.4266.73 17.7269.11
3. Mood/Apathy 0.0060.00 1.0661.63 3.9764.56 7.3467.33 20.52614.26
4. Perceptual problems 0.0060.00 0.2060.90 0.5261.41 1.1062.73 4.5066.00
5. Attention/Memory 0.0060.00 0.8161.26 2.7363.58 5.5965.98 11.7069.65
6. Gastrointestinal 0.0060.00 1.3462.04 3.1264.04 6.0065.39 11.1068.50
7. Urinary 0.0060.00 1.5962.24 4.7364.96 8.9068.00 16.07610.02
8. Sexual function 0.0060.00 0.4961.53 1.7963.25 3.7465.11 7.4468.30
9. Miscellaneous 0.0060.00 1.3461.84 4.8664.88 8.3467.60 12.9968.81
NMSS Total score 0.0060.00 9.0164.05 27.8066.89 51.8967.97 106.03634.56
*Kruskal-Wallis test for all variables, p= 0.0001.
Bonferroni correction for multiple (n=22) comparisons, p,0.0023.
NMS: Non-Motor Symptoms. NMSS: Non-Motor Symptoms Scale.
doi:10.1371/journal.pone.0057221.t002
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limitations to this exploratory work. Firstly we do not have control
data for this study although in the validation of our NMS
instruments a collection of healthy control data was obtained
showing that while some NMS such as insomnia, nocturia and
pain may be common amongst controls, the severity of these
symptoms is considerably greater in PD [39]. Additionally, the
proposed classification is not aimed at discrimination of PD from
controls and it would not be feasible to apply the HY classification
to a control population.
An important limitation of the study is its selection bias, as
patients were recruited from specialized units of tertiary centres
and, therefore, findings may not be generalizable to the entire PD
population. The most advanced phases of disease were under-
represented and this may have influenced results leading, for
example, to false high correlations between motor and non-motor
problems for HY stage 5.
Like many studies evaluating symptoms, we used a relatively
‘‘cognitively intact’’ cohort. As such one may argue that lack of
inclusion of patients with dementia would be a drawback of this
study. We would, however, point out that only patients with
‘‘overt’’ dementia were excluded and the sample studied includes
patients with cognitive impairment and would be reflective of PD
population normally seen in clinics spanning untreated to
Table 3. Variables in the study broken down by the NMS burden levels and Hoehn and Yahr staging*.
Non-Motor Symptoms Burden Levels
No Mild Moderate Severe Very severe
Level 0 1 2 3 4
NMSS score 0 1–20 21–40 41–70 $71
n (935) 5 244 233 218 235
PD Duration 2.8062.49 5.8864.68 7.6464.99 8.3865.21 10.1667.12
SCOPA-Motor
A. Examination 4.0061.87 9.5465.16 10.3565.56 12.1666.11 14.8967.94
B. ADL 0.0060.00 4.7063.11 5.9363.12 7.3363.72 9.6564.72
C. Complications 0.4060.89 1.4362.27 2.2862.55 3.0762.80 4.1163.57
Total score 4.4062.07 15.6868.85 18.5569.04 22.56610.68 28.57614.35
CISI-PD Total 1.8061.10 5.5263.19 7.1963.55 9.0264.04 11.5565.04
EQ-5D Index 1.0060.00 0.7860.23 0.6860.28 0.6060.29 0.3660.38
EQ-VAS 75.80637.43 66.73622.65 65.08620.86 63.11620.86 54.35621.62
PDQ-8 Index 6.25610.60 19.88617.85 25.80615.89 31.51616.87 45.70619.05
Hoehn and Yahr Staging
12345
n (949) 125 412 284 108 20
PD Duration 3.7762.55 6.9164.68 9.2465.38 11.7566.84 19.1068.93
SCOPA-Motor
A. Examination 5.8263.08 9.2464.24 13.5065.30 19.6166.52 27.8065.68
B. ADL 3.1262.73 5.2262.77 7.8062.58 12.4263.16 19.0561.43
C. Complications 0.5061.20 1.6162.20 3.7762.85 5.5763.12 7.5563.71
Total score 9.4565.33 16.0866.93 25.0168.02 37.6169.90 54.4068.85
CISI-PD Total 3.5062.05 6.1762.77 10.4063.28 14.0563.71 18.8063.07
EQ-5D Index 0.7960.23 0.7160.25 0.5460.30 0.3560.41 20.1760.35
EQ-VAS 72.22620.33 66.70620.32 58.10621.50 50.30621.92 41.25623.00
PDQ-8 Index 19.52615.85 25.16617.02 34.79618.90 46.03619.20 60.94622.25
PD: Parkinson’s disease. NMS: Non-Motor Symptoms. NMSS: Non-Motor Symptoms Scale. SCOPA: Scales for Outcomes in Parkinson’s Disease. CISI-PD: Clinical Impression
of Severity Index for Parkinson’s disease. VAS: Visual analogue scale. PDQ-8: Parkinson’s Disease Questionnaire-8 items.
*Kruskal-Wallis test for all variables, p= 0.0001. Bonferroni correction for multiple (n=18) comparisons, p,0.0027.
doi:10.1371/journal.pone.0057221.t003
Table 4. Patients classification by Hoehn and Yahr staging
and Non-Motor Symptoms burden levels.
Hoehn and Yahr Stages Non-Motor burden levels Total
0 1234
1 3 55 38 19 9 124
2 2 126 122 87 67 404
3 0 55 56 81 88 280
4 0 7 1 62 95 41 0 6
5 0 0121 6 1 9
Total 5 243 233 218 234 933
Goodman and Kruskal’s gamma=0.45; ASE=0.032.
doi:10.1371/journal.pone.0057221.t004
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other scales would be difficult to complete in patients with frank
dementia.
NMSS relates to symptoms over the ‘‘last month’’. The
assessments are done largely in ‘‘on’’ state and reflect the fact
that this work is aimed at a ‘‘global’’ assessment which
encapsulates ‘‘on’’ and ‘‘off’’ phases while recording NMS.
Furthermore, also were included patients in early disease states
who are either untreated or do not have clearly defined on and off
fluctuations. Nonetheless, in the present study, comparison
between the NMS levels and the motor HY staging (Table 4) is
only valid for patients "on" medication, as the "off" medication
state was not considered and this fact could substantially modify
the results..
It is possible that NMS recorded may be modified by
dopaminergic therapies however, in this study as we are evaluating
motor and NMS at the point of examination, it is irrelevant if the
patient has drug related NMS as this study cannot identify the
cause of the NMS. Additionally, the identification of a high NMS
load in such a case, for instance, may allow the clinician to address
drug related causation.
We, therefore, propose that a combined motor staging (with
HY) and NMS burden classification (from grade 0–4) be adopted
for use in clinical practice. Further large scale longitudinal and
clinico-pathological correlation studies are now required to define
the prognostic and clinical value of the NMSB grading strategy.
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